Am. J. Respir. Crit. Care Med., Volume 160, Number 1, July 1999, 203-210

Measurement of Sputum Mycobacterium tuberculosis Messenger RNA as a Surrogate for Response to Chemotherapy

LUCY E. DESJARDIN, MARK D. PERKINS, KATHY WOLSKI, SHIRLEY HAUN, LUCILÉIA TEIXEIRA, YING CHEN, JOHN L. JOHNSON, JERROLD J. ELLNER, REYNALDO DIETZE, JOSEPH BATES, M. DONALD CAVE, and KATHLEEN D. EISENACH

Departments of Pathology, Anatomy, Medicine and Microbiology, University of Arkansas for Medical Sciences and J. L. McClellan Memorial VA Hospital, Little Rock, Arkansas; Department of Medicine, Duke University Medical Center, Durham, North Carolina; Department of Medicine, Case Western Reserve University, Cleveland, Ohio; and Núcleo de Doencas Infecciosas, Universidade Federal do Espìrito Santo, Vitória, Brazil

Effective treatment regimens for pulmonary tuberculosis are difficult to assess because of the slow growth rate of Mycobacterium tuberculosis in culture and its protracted clearance from sputum. A rapid method that reflects effective antimicrobial activity would markedly advance evaluation of treatment and promote the assessment of new antituberculosis drugs. Conventional methods measure the progressive reduction of numbers of acid-fast bacilli in the sputum smear and the clearance of organisms in sputum culture. In this study, we measured levels of M. tuberculosis 85B (alpha antigen) messenger RNA (mRNA), 16S ribosomal RNA (rRNA), and IS6110 DNA in patients' sputa to ascertain whether they could serve as potential surrogate markers of response to chemotherapy. Sputum specimens were sequentially collected for up to a year from 19 smear-positive pulmonary tuberculosis patients receiving an optimal drug treatment regimen. Nucleic acids were isolated from these specimens, and two M. tuberculosis molecular targets (mRNA, DNA) were quantified, using the ABI Prism 7700 Sequence Detection System. The Mycobacterium genus-specific 16S rRNA was quantified with a limiting dilution RT-PCR assay. Results show that levels of 85B mRNA declined after initiation of therapy, as did viable M. tuberculosis colony counts, with 90% of patients becoming negative for both markers after 2 mo of treatment. The rapid disappearance of M. tuberculosis mRNA from sputum suggests that it is a good indicator of microbial viability and a useful marker for rapid assessment of response to chemotherapy.

This article has been cited by other articles:

				N. Mdivani, H. Li, M. Akhalaia, M. Gegia, L. Goginashvili, D. S. Kernodle, G. Khechinashvili, and Y.-W. Tang Monitoring Therapeutic Efficacy by Real-Time Detection of Mycobacterium tuberculosis mRNA in Sputum Clin. Chem., September 1, 2009; 55(9): 1694 - 1700. [Abstract] [Full Text] [PDF]

				A. N. Martinez, R. Lahiri, T. L. Pittman, D. Scollard, R. Truman, M. O. Moraes, and D. L. Williams Molecular Determination of Mycobacterium leprae Viability by Use of Real-Time PCR J. Clin. Microbiol., July 1, 2009; 47(7): 2124 - 2130. [Abstract] [Full Text] [PDF]

				D. Huang, Y. Shen, L. Qiu, C. Y. Chen, L. Shen, J. Estep, R. Hunt, D. Vasconcelos, G. Du, P. Aye, et al. Immune Distribution and Localization of Phosphoantigen-Specific V{gamma}2V{delta}2 T Cells in Lymphoid and Nonlymphoid Tissues in Mycobacterium tuberculosis Infection Infect. Immun., January 1, 2008; 76(1): 426 - 436. [Abstract] [Full Text] [PDF]

				G. R. Stewart, K. A. Wilkinson, S. M. Newton, S. M. Sullivan, O. Neyrolles, J. R. Wain, J. Patel, K.-L. Pool, D. B. Young, and R. J. Wilkinson Effect of Deletion or Overexpression of the 19-Kilodalton Lipoprotein Rv3763 on the Innate Response to Mycobacterium tuberculosis Infect. Immun., October 1, 2005; 73(10): 6831 - 6837. [Abstract] [Full Text] [PDF]

				K. A. Wilkinson, G. R. Stewart, S. M. Newton, H. M. Vordermeier, J. R. Wain, H. N. Murphy, K. Horner, D. B. Young, and R. J. Wilkinson Infection Biology of a Novel {alpha}-Crystallin of Mycobacterium tuberculosis: Acr2 J. Immunol., April 1, 2005; 174(7): 4237 - 4243. [Abstract] [Full Text] [PDF]

				S. Rondini, E. Mensah-Quainoo, H. Troll, T. Bodmer, and G. Pluschke Development and Application of Real-Time PCR Assay for Quantification of Mycobacterium ulcerans DNA J. Clin. Microbiol., September 1, 2003; 41(9): 4231 - 4237. [Abstract] [Full Text] [PDF]

				American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of Tuberculosis Am. J. Respir. Crit. Care Med., February 15, 2003; 167(4): 603 - 662. [Full Text] [PDF]

				A. Garcia-Quintanilla, J. Gonzalez-Martin, G. Tudo, M. Espasa, and M. T. Jimenez de Anta Simultaneous Identification of Mycobacterium Genus and Mycobacterium tuberculosis Complex in Clinical Samples by 5'-Exonuclease Fluorogenic PCR J. Clin. Microbiol., December 1, 2002; 40(12): 4646 - 4651. [Abstract] [Full Text] [PDF]

				G. Fenhalls, L. Stevens, L. Moses, J. Bezuidenhout, J. C. Betts, P. v. Helden, P. T. Lukey, and K. Duncan In Situ Detection of Mycobacterium tuberculosis Transcripts in Human Lung Granulomas Reveals Differential Gene Expression in Necrotic Lesions Infect. Immun., November 1, 2002; 70(11): 6330 - 6338. [Abstract] [Full Text] [PDF]

				K. C. Chapin, P. Blake, and C. D. Wilson Performance Characteristics and Utilization of Rapid Antigen Test, DNA Probe, and Culture for Detection of Group A Streptococci in an Acute Care Clinic J. Clin. Microbiol., November 1, 2002; 40(11): 4207 - 4210. [Abstract] [Full Text] [PDF]

				R. Ribeiro-Rodrigues, T. Resende Co, J. L. Johnson, F. Ribeiro, M. Palaci, R. T. Sa, E. L. Maciel, F. E. Pereira Lima, V. Dettoni, Z. Toossi, et al. Sputum Cytokine Levels in Patients with Pulmonary Tuberculosis as Early Markers of Mycobacterial Clearance Clin. Vaccine Immunol., July 1, 2002; 9(4): 818 - 823. [Abstract] [Full Text] [PDF]

				R. J. O'Brien Studies of the Early Bactericidal Activity of New Drugs for Tuberculosis: A Help or a Hindrance to Antituberculosis Drug Development? Am. J. Respir. Crit. Care Med., July 1, 2002; 166(1): 3 - 4. [Full Text] [PDF]

				L. E. DesJardin, L. G. Hayes, C. D. Sohaskey, L. G. Wayne, and K. D. Eisenach Microaerophilic Induction of the Alpha-Crystallin Chaperone Protein Homologue (hspX) mRNA of Mycobacterium tuberculosis J. Bacteriol., September 15, 2001; 183(18): 5311 - 5316. [Abstract] [Full Text] [PDF]

				R. Dietze, L. Teixeira, L. M. C. Rocha, M. Palaci, J. L. Johnson, C. Wells, L. Rose, K. Eisenach, and J. J. Ellner Safety and Bactericidal Activity of Rifalazil in Patients with Pulmonary Tuberculosis Antimicrob. Agents Chemother., July 1, 2001; 45(7): 1972 - 1976. [Abstract] [Full Text] [PDF]

				R. J. O'BRIEN and P. P. NUNN The Need for New Drugs against Tuberculosis . Obstacles, Opportunities, and Next Steps Am. J. Respir. Crit. Care Med., April 1, 2001; 163(5): 1055 - 1058. [Full Text]

				F. A. Sirgel, P. R. Donald, J. Odhiambo, W. Githui, K. C. Umapathy, C. N. Paramasivan, C. M. Tam, K. M. Kam, C. W. Lam, K. M. Sole, et al. A multicentre study of the early bactericidal activity of anti-tuberculosis drugs J. Antimicrob. Chemother., June 1, 2000; 45(6): 859 - 870. [Abstract] [Full Text] [PDF]